ATE404174T1 - Impfstoff zur transmukosalen verabreichung - Google Patents

Impfstoff zur transmukosalen verabreichung

Info

Publication number: ATE404174T1
Authority: AT; Austria
Prior art keywords: chitosan; lectins; vaccines; antigens; vaccine
Prior art date: 2001-03-19

Application number

AT02006076T

Other languages

English (en)

Inventor

Rolando Wyss

Bernard Bizzini

Ivo Volpato

Original Assignee

Grisotech S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-19

Filing date

2002-03-18

Publication date

2008-08-15

2002-03-18 Application filed by Grisotech S A filed Critical Grisotech S A

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404174T1 publication Critical patent/ATE404174T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 3
229920001661 Chitosan Polymers 0.000 abstract 3
102000004856 Lectins Human genes 0.000 abstract 2
108090001090 Lectins Proteins 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
239000000470 constituent Substances 0.000 abstract 2
239000002523 lectin Substances 0.000 abstract 2
229920001282 polysaccharide Polymers 0.000 abstract 2
239000005017 polysaccharide Substances 0.000 abstract 2
150000004804 polysaccharides Chemical class 0.000 abstract 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 abstract 1
102000010911 Enzyme Precursors Human genes 0.000 abstract 1
108010062466 Enzyme Precursors Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229920000615 alginic acid Polymers 0.000 abstract 1
229960001126 alginic acid Drugs 0.000 abstract 1
235000010443 alginic acid Nutrition 0.000 abstract 1
239000000783 alginic acid Substances 0.000 abstract 1
150000004781 alginic acids Chemical class 0.000 abstract 1
239000013566 allergen Substances 0.000 abstract 1
230000000975 bioactive effect Effects 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000012678 infectious agent Substances 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
239000004081 narcotic agent Substances 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
235000013311 vegetables Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Hematology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Virology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT02006076T 2001-03-19 2002-03-18 Impfstoff zur transmukosalen verabreichung ATE404174T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001MI000571A ITMI20010571A1 (it)	2001-03-19	2001-03-19	Vaccini assorbibili per via trans-mucosale

Publications (1)

Publication Number	Publication Date
ATE404174T1 true ATE404174T1 (de)	2008-08-15

Family

ID=11447301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02006076T ATE404174T1 (de)	2001-03-19	2002-03-18	Impfstoff zur transmukosalen verabreichung

Country Status (6)

Country	Link
US (2)	US6936250B2 (de)
EP (1)	EP1243256B1 (de)
JP (1)	JP2002326953A (de)
AT (1)	ATE404174T1 (de)
DE (1)	DE60228154D1 (de)
IT (1)	ITMI20010571A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8012505B2 (en)	2003-02-28	2011-09-06	Alk-Abello A/S	Dosage form having a saccharide matrix
AU2004216559B2 (en) *	2003-02-28	2010-05-27	Alk-Abello A/S	Dosage form having a saccharide matrix
US20050175679A1 (en) *	2004-02-10	2005-08-11	Michael Moshman	Controlled release formulations
JPWO2006019183A1 (ja) *	2004-08-18	2008-05-08	国立大学法人徳島大学	粘膜免疫、その感作剤を用いる粘膜ワクチン及び予防接種システム
CA2581330A1 (en) *	2004-09-21	2006-03-30	The Brigham And Women's Hospital, Inc.	Methods and compositions relating to mannuronic acid specific binding peptides
EP1843819A2 (de) *	2004-11-15	2007-10-17	Obe Therapy Biotechnology S.A.S.	Verfahren zur reduzierung von körperfett
WO2006092799A1 (en) *	2005-03-02	2006-09-08	Polyrizon Ltd.	Method for removal of toxins from mucosal membranes
BRPI0609932A2 (pt) *	2005-05-24	2011-10-11	Neovacs	métodos para preparar um produto imunogênico anti-tnfalfa e para preparar uma composição de vacina, produto imunogênico anti-tnfalfa, composição imunogênica, e, composição de vacina
NZ590010A (en)	2008-06-25	2013-01-25	Braasch Biotech Llc	Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
WO2012156376A1 (en) *	2011-05-13	2012-11-22	Merrion Pharmaceuticals Ireland Ltd.	Use of plant lectins to target leukocytes
ITFI20110140A1 (it) *	2011-07-18	2013-01-19	In Fieri S R L	Composizione ad uso topico per il trattamento delle alopecie
ITMI20121597A1 (it) *	2012-09-25	2014-03-26	Beta Pharma S A	Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
ITPI20130093A1 (it) *	2013-11-06	2015-05-07	Laura Ferrari	Composizione per la prevenzione e il trattamento della psoriasi e di patologie infiammatorie cutanee
CN107929728A (zh) *	2017-04-19	2018-04-20	武汉博沃生物科技有限公司	一种肺炎球菌蛋白疫苗及其制备方法
CN108785666A (zh) *	2018-06-05	2018-11-13	中国医学科学院生物医学工程研究所	一种应用于肝癌免疫治疗的dc靶向性纳米疫苗及其制备方法
WO2024218752A1 (en) *	2023-04-21	2024-10-24	Instar Technologies A.S.	Pharmaceutical composition for vaccination against cytomegalovirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4470967A (en) *	1982-10-05	1984-09-11	Iowa State University Research Foundation	Lectin-containing anti-viral vaccines for domestic animals and method of preparation
DE4033446A1 (de)	1990-10-20	1992-04-23	Bayer Ag	Impfstoffe gegen equine herpesviren und ihre herstellung
GB9419979D0 (en) *	1994-10-04	1994-11-16	Medeva Holdings Bv	Vaccine compositions
US5900238A (en) *	1995-07-27	1999-05-04	Immunex Corporation	Vaccine delivery system
EP2275133A1 (de)	1999-02-26	2011-01-19	Novartis Vaccines and Diagnostics, Inc.	Verwendung von Bioklebstoffen und Impfstoff-Adjuvantien für mucosale Verabreichung von antigenem Material

2001
- 2001-03-19 IT IT2001MI000571A patent/ITMI20010571A1/it unknown
2002
- 2002-03-18 EP EP02006076A patent/EP1243256B1/de not_active Expired - Lifetime
- 2002-03-18 DE DE60228154T patent/DE60228154D1/de not_active Expired - Lifetime
- 2002-03-18 US US10/101,034 patent/US6936250B2/en not_active Expired - Fee Related
- 2002-03-18 AT AT02006076T patent/ATE404174T1/de not_active IP Right Cessation
- 2002-03-19 JP JP2002077103A patent/JP2002326953A/ja active Pending
2005
- 2005-07-25 US US11/189,221 patent/US7186411B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1243256B1 (de)	2008-08-13
US20050260228A1 (en)	2005-11-24
US20030049279A1 (en)	2003-03-13
DE60228154D1 (de)	2008-09-25
US7186411B2 (en)	2007-03-06
ITMI20010571A1 (it)	2002-09-19
EP1243256A1 (de)	2002-09-25
US6936250B2 (en)	2005-08-30
JP2002326953A (ja)	2002-11-15

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60228154D1 (de)	2008-09-25	Impfstoff zur transmukosalen Verabreichung
WO2005104755A3 (en)	2008-08-21	Artificial immune system: methods for making and use
WO2008073635A3 (en)	2008-08-28	Automatable artificial immune system (ais)
ATA1292000A (de)	2001-10-15	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
NO20023829L (no)	2002-08-13	Proteosom influensavaksine
UA91044C2 (uk)	2010-06-25	Жива послаблена ротавірусна вакцина для перорального застосування
MX2009001412A (es)	2009-04-24	Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EP2484375A3 (de)	2012-08-15	Impfstoffzusammensetzung mit einem synthetischen Adjuvans
BRPI0507680A (pt)	2007-07-17	partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
WO2008108794A3 (en)	2009-01-22	Controlling dendritic cell maturation state in the lymphoid tissue equivalent of an artificial immune system
WO2007106559A3 (en)	2008-04-03	An in vitro mucosal tissue equivalent
WO2003061578A3 (en)	2003-12-04	Compositions for treatment or prevention of bioterrorism
DE60131760D1 (de)	2008-01-17	Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
WO2007146267A3 (en)	2008-06-05	Disease model incorporation into an artificial immune system (ais)
WO2006110728A3 (en)	2007-12-06	Immunogenic cmv tegument aggregates
DE60012042D1 (de)	2004-08-12	Entepneumovirus und entsprechendes impfstoff
EP1855719A4 (de)	2009-11-04	Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
EP2432893A4 (de)	2013-06-19	Zusammensetzungen, kits und verfahren zur in-vitro-antigen-darstellung, zur überprüfung der wirksamkeit eines impfstoffs und zur überprüfung der immuntoxizität von biologischen stoffen und arzneimitteln
ATE511855T1 (de)	2011-06-15	Adjuvansformulierung zur scheimhaut-applikation
AR049063A1 (es)	2006-06-21	Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
WO2008054535A3 (en)	2008-07-31	Novel influenza m2 vaccines
WO2006029248A3 (en)	2009-05-28	Hollow fiber technique for in vivo study of cell populations
ATE406874T1 (de)	2008-09-15	Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
WO2005058006A3 (en)	2006-03-23	Methods and compositions comprising bacteriophage nanoparticles
PT1951300E (pt)	2011-09-05	Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes